These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 36066204)
21. Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era. Li Y; Zhang X; Zou Z; Xiong Y; Gu X; Zou R; Tan J; Zhang L; Zheng Y; Niu T Clin Exp Med; 2024 Sep; 24(1):215. PubMed ID: 39249542 [TBL] [Abstract][Full Text] [Related]
22. Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma - The Oregon Health and Science University Experience. Galligan D; Williamson S; Myers J; Silbermann R; Medvedova E; Nagle S; Schachter L; Chen A; Scott E; Maziarz R Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):105-112. PubMed ID: 34686447 [TBL] [Abstract][Full Text] [Related]
23. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157 [TBL] [Abstract][Full Text] [Related]
24. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684 [TBL] [Abstract][Full Text] [Related]
25. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110 [TBL] [Abstract][Full Text] [Related]
26. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717 [TBL] [Abstract][Full Text] [Related]
27. Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation. Mikulski D; Kościelny K; Nowicki M; Wawrzyniak E; Kalwas M; Kowalik M; Pryt M; Sęczkowska E; Świątek A; Wierzbowska A; Fendler W Leuk Lymphoma; 2023 Jan; 64(1):98-106. PubMed ID: 36318865 [TBL] [Abstract][Full Text] [Related]
28. Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agents in patients older than 65 years with multiple myeloma. Sato S; Tsunoda S; Kawahigashi T; Kamata W; Tamai Y Ann Hematol; 2023 May; 102(5):1185-1191. PubMed ID: 36951968 [TBL] [Abstract][Full Text] [Related]
29. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913 [TBL] [Abstract][Full Text] [Related]
30. Autologous stem cell transplantation for multiple myeloma: Long-term results. Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994 [TBL] [Abstract][Full Text] [Related]
31. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Dispenzieri A; Wiseman GA; Lacy MQ; Hayman SR; Kumar SK; Buadi F; Dingli D; Laumann KM; Allred J; Geyer SM; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Johnston PB; Hogan WJ; Gertz MA Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117 [TBL] [Abstract][Full Text] [Related]
32. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964 [TBL] [Abstract][Full Text] [Related]
33. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081 [TBL] [Abstract][Full Text] [Related]
34. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250 [TBL] [Abstract][Full Text] [Related]
35. Final outcomes of escalated melphalan 280 mg/m Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806 [TBL] [Abstract][Full Text] [Related]
36. Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT; Lonial S; Nooka AK Transplant Cell Ther; 2022 Feb; 28(2):75.e1-75.e7. PubMed ID: 34626863 [TBL] [Abstract][Full Text] [Related]
37. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study. Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830 [TBL] [Abstract][Full Text] [Related]
38. Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma. Parrish C; Rahemtulla A; Cavet J; Pearce RM; Kirkland K; Lee J; Cook M; Wilson K; Cook G; Biol Blood Marrow Transplant; 2015 Jul; 21(7):1330-4. PubMed ID: 25843652 [TBL] [Abstract][Full Text] [Related]
39. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma]. Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356 [TBL] [Abstract][Full Text] [Related]